propiverine has been researched along with Urinary Incontinence in 48 studies
propiverine: anticholinergic used for overactive bladder syndrome
Urinary Incontinence: Involuntary loss of URINE, such as leaking of urine. It is a symptom of various underlying pathological processes. Major types of incontinence include URINARY URGE INCONTINENCE and URINARY STRESS INCONTINENCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, comparative study, 104 patients who were aware of urinary incontinence after RALP or LRP were assigned to receive propiverine hydrochloride (treatment group) or not (controls)." | 9.41 | Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy. ( Matsuo, T; Mitsunari, K; Miyata, Y; Mukae, Y; Ohba, K; Sakai, H, 2021) |
| "To show the efficacy of propiverine hydrochloride in the management of symptoms of stress urinary incontinence in female patients with mixed-type urinary incontinence." | 9.27 | Therapeutic effect of propiverine hydrochloride on mixed-type urinary incontinence in women: The Female Urgency and Stress Urinary Incontinence Study of Propiverine Hydrochloride trial. ( Gotoh, M; Kaga, K; Kawahara, K; Kikuchi, T; Minagawa, T; Nishizawa, O; Sugaya, K; Yamanishi, T; Yokoyama, O, 2018) |
| "This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence." | 9.14 | Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. ( Feustel, C; Marschall-Kehrel, D; Persson de Geeter, C; Radmayr, C; Sillén, U; Stehr, M; Strugala, G, 2009) |
| "In a total of 46 dementia patients with urinary incontinence, filling cystometry was performed to evaluate bladder function, followed by peroral administration of propiverine hydrochloride." | 9.09 | [Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride]. ( Kojima, M; Mori, S; Nakajima, K; Sakai, Y, 1999) |
| "The present study evaluated the effects of clenbuterol and propiverine therapy on postmenopausal urinary incontinence." | 9.09 | Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence: improvement in quality of life. ( Ikeda, A; Ueki, M; Ushiroyama, T, 2000) |
| "Propiverine hydrochloride was given to patients with subjective symptoms of urinary incontinence and its effect was evaluated in relation to the pathogenesis of incontinence." | 9.08 | [Clinical effect of propiverine hydrochloride on urinary incontinence]. ( Kojima, M; Uchida, M; Watanabe, H, 1998) |
| "In this randomized, comparative study, 104 patients who were aware of urinary incontinence after RALP or LRP were assigned to receive propiverine hydrochloride (treatment group) or not (controls)." | 5.41 | Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy. ( Matsuo, T; Mitsunari, K; Miyata, Y; Mukae, Y; Ohba, K; Sakai, H, 2021) |
| "This clinical trial showed superior efficacy of propiverine over placebo and good tolerability for the treatment of children suffering from OAB and urinary incontinence." | 5.14 | Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial. ( Feustel, C; Marschall-Kehrel, D; Persson de Geeter, C; Radmayr, C; Sillén, U; Stehr, M; Strugala, G, 2009) |
| "In a total of 46 dementia patients with urinary incontinence, filling cystometry was performed to evaluate bladder function, followed by peroral administration of propiverine hydrochloride." | 5.09 | [Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride]. ( Kojima, M; Mori, S; Nakajima, K; Sakai, Y, 1999) |
| "Propiverine hydrochloride was given to patients with subjective symptoms of urinary incontinence and its effect was evaluated in relation to the pathogenesis of incontinence." | 5.08 | [Clinical effect of propiverine hydrochloride on urinary incontinence]. ( Kojima, M; Uchida, M; Watanabe, H, 1998) |
| " Furthermore, NS-21 increased the bladder capacity without suppressing micturition pressure, suggesting that NS-21 may be a more effective therapeutic drug than propiverine, oxybutynin or flavoxate for the treatment of urinary frequency and urinary incontinence." | 3.69 | Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency. ( Hamada, K; Kimura, K; Kimura, Y; Sasaki, Y; Seto, T; Ukai, Y; Yamazaki, C; Yoshikuni, Y, 1997) |
| "In a post-marketing surveillance study of 752 patients suffering from urgent incontinence, mixed urgent-stress incontinence, reflex incontinence, urgency and enuresis were treated with propiverine hydrochloride." | 3.69 | [Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of detrusor hyperactivity and increased sensitivity and irritability of the urinary bladder: results of a study monitoring drug utilization]. ( Halaska, M; Kaplan, F; Klemenc, J; Martan, A; Masata, J; Raus, K; Voigt, R, 1997) |
| "The clinical effectiveness and safety of propiverine hydrochloride (P-4, 20 mg tablet) were studied on 29 patients with nervous pollakisuria, neurogenic bladder or unstable bladder, whose chief complaints were urinary frequency and/or urinary incontinence." | 3.68 | [Experience in the use of propiverine hydrochloride (P-4) for patients suffering from urinary frequency and/or incontinence]. ( Fujita, Y; Hisazumi, H; Ishida, T; Miyazaki, K; Yokoyama, O, 1990) |
| " Safety assessments included treatment-emergent adverse events, vital signs, 12-lead electrocardiograms, post-void residual volume, and laboratory evaluations." | 2.90 | Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study). ( Gotoh, M; Hamada, T; Homma, Y; Igawa, Y; Kakizaki, H; Kobayashi, A; Kuroishi, K; Nishizawa, O; Okitsu, A; Seki, N; Takeda, M; Yamaguchi, O; Yokoyama, O; Yoshida, M, 2019) |
| "Imidafenacin was not inferior to propiverine for the reduction of UUI episodes, and was better tolerated than propiverine in the safety profile." | 2.79 | A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder. ( Choo, MS; Kim, DY; Kim, JC; Lee, JG; Lee, JZ; Lee, KS; Lee, SJ; Park, C; Park, J; Seo, JT, 2014) |
| "Oxybutynin 15 mg was more effective than propiverine 20 mg in reducing symptomatic and asymptomatic IDCs in ambulatory patients." | 2.72 | Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. ( Abrams, P; Cardozo, L; Chapple, C; Hargreaves, K; Khullar, V; Serdarevic, D, 2006) |
| " The incidence of adverse events was very low (2 % dryness of the mouth under propiverine) and confirmed by the findings from the quality of life questionnaires." | 2.71 | [The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine]. ( Brünjes, R; Dorschner, W; Frank, M; Griebenow, R; Halaska, M; Stolzenburg, JU; Wieners, F, 2003) |
| " The dosages were selected specifically to compare the tolerability profile of propiverine with the commonly used therapeutic dosage of oxybutynin." | 2.69 | A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. ( Alloussi, S; Halaska, M; Höfner, K; Madersbacher, H; Voigt, R, 1999) |
| " Individual treatment with an initial dosage of 30 mg/d should be recommended." | 2.68 | Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study. ( Alken, RG; Dorschner, W; Herfurth, G; Mazur, D; Schubert, G; Wehnert, J, 1995) |
| " The application period was 4 weeks and the dosage was 45 mg/d Mictonorm and 300 mg/d Spasuret, respectively." | 2.66 | [Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle]. ( Sage, S; Wehnert, J, 1989) |
| " The AMs used to treat OAB differ in their pharmacological profiles, which may affect their potential for causing adverse effects (AEs)." | 2.48 | Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females. ( Alessandri, F; Candiani, M; Ferrero, S; Leone Roberti Maggiore, U; Origoni, M; Remorgida, V; Salvatore, S; Venturini, PL, 2012) |
| "The propiverine group was given propiverine orally once a day for 2 weeks, after which urethral function and plasma concentrations of catecholamine (dopamine, norepinephrine, epinephrine) were tested." | 1.39 | Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats. ( Kiniwa, M; Kitta, T; Nanri, M; Nonomura, K; Tyagi, V; Yoshimura, N, 2013) |
| "Propiverine monotherapy was well tolerated in 11/17 patients." | 1.38 | Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study. ( Austin, P; Heine, G; Knispel, HH; Michael, T; Miller, K; Mürtz, G; Schulte-Baukloh, H; Strugala, G, 2012) |
| " The urodynamic measurements as well as pharmacokinetic samplings were done before the medication, 4 weeks and 8 weeks after the starting medication, to examine the dose-response and concentration-response relationships." | 1.33 | [Pharmacological evaluation of efficacy and safety of propiverine hydrochloride in patients of overactive bladder--relationship between urodynamic observation and propiverine pharmacokinetics--]. ( Hanai, T; Hashimoto, K; Matsumoto, S; Shimizu, N; Sugiyama, T; Uemura, H; Yoshioka, N, 2005) |
| "Propiverine hydrochloride is a preferable alternative to oxybutynin, the anticholinergic most frequently used in children with NDO to date." | 1.33 | Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis. ( Henne, T; Knispel, HH; Michael, T; Miller, K; Mürtz, G; Schulte-Baukloh, H, 2006) |
| "Propiverine (0." | 1.32 | An empirical treatment algorithm for incontinent children. ( Jünemann, KP; Kramer, G; Madersbacher, H; Marschall-Kehrel, AD; Mürtz, G, 2004) |
| " Mictonorm was given for 3 months, in a dosage of 0,4 mg/kg bw/d." | 1.27 | [Treatment of the unstable bladder in children with the anticholinergic agent propiverin hydrochloride (mictonorm/mictonets)]. ( Otto-Unger, G, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (18.75) | 18.7374 |
| 1990's | 9 (18.75) | 18.2507 |
| 2000's | 20 (41.67) | 29.6817 |
| 2010's | 8 (16.67) | 24.3611 |
| 2020's | 2 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Müderrisoglu, AE | 1 |
| Oelke, M | 1 |
| Schneider, T | 1 |
| Murgas, S | 1 |
| de la Rosette, JJMCH | 1 |
| Michel, MC | 1 |
| Ohba, K | 1 |
| Miyata, Y | 1 |
| Mukae, Y | 1 |
| Mitsunari, K | 1 |
| Matsuo, T | 1 |
| Sakai, H | 1 |
| Minagawa, T | 1 |
| Gotoh, M | 3 |
| Yokoyama, O | 4 |
| Sugaya, K | 1 |
| Yamanishi, T | 1 |
| Kawahara, K | 1 |
| Kaga, K | 1 |
| Kikuchi, T | 1 |
| Nishizawa, O | 3 |
| Masumori, N | 1 |
| Funato, Y | 1 |
| Yamaguchi, Y | 1 |
| Itoh, K | 1 |
| Yamaguchi, O | 1 |
| Kakizaki, H | 1 |
| Homma, Y | 2 |
| Igawa, Y | 1 |
| Takeda, M | 1 |
| Yoshida, M | 1 |
| Seki, N | 1 |
| Okitsu, A | 1 |
| Hamada, T | 1 |
| Kobayashi, A | 1 |
| Kuroishi, K | 1 |
| Park, C | 1 |
| Park, J | 1 |
| Choo, MS | 3 |
| Kim, JC | 2 |
| Lee, JG | 1 |
| Lee, JZ | 1 |
| Lee, KS | 3 |
| Kim, DY | 2 |
| Lee, SJ | 1 |
| Seo, JT | 1 |
| Ates, F | 1 |
| Akyol, I | 1 |
| Cirakoglu, A | 1 |
| Schulte-Baukloh, H | 2 |
| Mürtz, G | 4 |
| Heine, G | 1 |
| Austin, P | 1 |
| Miller, K | 2 |
| Michael, T | 2 |
| Strugala, G | 2 |
| Knispel, HH | 2 |
| Leone Roberti Maggiore, U | 1 |
| Salvatore, S | 1 |
| Alessandri, F | 1 |
| Remorgida, V | 1 |
| Origoni, M | 1 |
| Candiani, M | 1 |
| Venturini, PL | 1 |
| Ferrero, S | 1 |
| Kitta, T | 1 |
| Tyagi, V | 1 |
| Nanri, M | 1 |
| Kiniwa, M | 1 |
| Nonomura, K | 1 |
| Yoshimura, N | 1 |
| Zozikov, B | 1 |
| Kunchev, SI | 1 |
| Varlev, C | 1 |
| Hader, C | 1 |
| Welz-Barth, A | 1 |
| Keller, T | 1 |
| Dorschner, W | 4 |
| Stolzenburg, JU | 1 |
| Griebenow, R | 1 |
| Halaska, M | 4 |
| Brünjes, R | 3 |
| Frank, M | 1 |
| Wieners, F | 1 |
| Marschall-Kehrel, AD | 1 |
| Kramer, G | 1 |
| Jünemann, KP | 2 |
| Madersbacher, H | 2 |
| Alloussi, S | 2 |
| Goepel, M | 1 |
| Richter, AE | 1 |
| Eberhardt, R | 1 |
| Zwingers, T | 1 |
| Song, C | 1 |
| Kim, JH | 1 |
| Choi, JB | 1 |
| Lee, JY | 1 |
| Chung, BS | 1 |
| Rittstein, T | 1 |
| Schnabel, F | 1 |
| Nurkiewicz, W | 1 |
| Kim, HJ | 1 |
| Min, KS | 1 |
| Lee, JB | 1 |
| Jeong, HJ | 1 |
| Lee, T | 1 |
| Park, WH | 1 |
| Athanasopoulos, A | 1 |
| Perimenis, P | 1 |
| Sugiyama, T | 1 |
| Shimizu, N | 1 |
| Hashimoto, K | 1 |
| Yoshioka, N | 1 |
| Hanai, T | 1 |
| Matsumoto, S | 1 |
| Uemura, H | 2 |
| Henne, T | 1 |
| Sahai, A | 1 |
| Khan, MS | 1 |
| Arya, M | 1 |
| John, J | 1 |
| Singh, R | 1 |
| Patel, HR | 1 |
| Noguchi, K | 2 |
| Yamagishi, T | 1 |
| Suzuki, K | 1 |
| Kondo, K | 1 |
| Kishida, T | 1 |
| Saito, K | 1 |
| Sekiguchi, Y | 1 |
| Nakaigawa, N | 1 |
| Ogawa, T | 1 |
| Yao, M | 1 |
| Kubota, Y | 2 |
| Kawai, M | 1 |
| Okajima, K | 1 |
| Kobayashi, K | 1 |
| Moriyama, M | 2 |
| Kinoshita, Y | 1 |
| Mikata, K | 1 |
| Kitami, K | 2 |
| Masuda, M | 2 |
| Saito, R | 1 |
| Murai, T | 1 |
| Tomoda, T | 1 |
| Noguchi, S | 2 |
| Sakai, N | 1 |
| Hamano, A | 1 |
| Nomura, S | 1 |
| Sato, K | 1 |
| Abrams, P | 1 |
| Cardozo, L | 1 |
| Chapple, C | 1 |
| Serdarevic, D | 1 |
| Hargreaves, K | 1 |
| Khullar, V | 1 |
| Takayanagi, R | 1 |
| Mizushima, H | 1 |
| Ozeki, T | 1 |
| Yokoyama, H | 1 |
| Iga, T | 1 |
| Yamada, Y | 1 |
| Lazzeri, M | 1 |
| Marschall-Kehrel, D | 1 |
| Feustel, C | 1 |
| Persson de Geeter, C | 1 |
| Stehr, M | 1 |
| Radmayr, C | 1 |
| Sillén, U | 1 |
| Blau, U | 1 |
| Retzke, U | 1 |
| Festge, B | 1 |
| Festge, OA | 1 |
| Rosenbaum, KD | 1 |
| Gross, W | 1 |
| Mazur, D | 1 |
| Wehnert, J | 2 |
| Schubert, G | 1 |
| Herfurth, G | 1 |
| Alken, RG | 1 |
| Sasaki, Y | 1 |
| Hamada, K | 1 |
| Yamazaki, C | 1 |
| Seto, T | 1 |
| Kimura, Y | 1 |
| Ukai, Y | 1 |
| Yoshikuni, Y | 1 |
| Kimura, K | 1 |
| Okada, H | 1 |
| Sengoku, J | 1 |
| Gohji, K | 1 |
| Arakawa, S | 1 |
| Kamidono, S | 1 |
| Watanabe, H | 1 |
| Uchida, M | 1 |
| Kojima, M | 2 |
| Martan, A | 1 |
| Voigt, R | 4 |
| Kaplan, F | 1 |
| Raus, K | 1 |
| Masata, J | 1 |
| Klemenc, J | 1 |
| Hosaka, M | 1 |
| Senga, Y | 1 |
| Sano, K | 1 |
| Miyai, K | 1 |
| Kanno, H | 1 |
| Fujinami, K | 1 |
| Miura, T | 1 |
| Kondo, I | 1 |
| Kawasaki, C | 1 |
| Hara, Y | 1 |
| Ida, T | 1 |
| Fukuoka, H | 1 |
| Nakagawa, J | 1 |
| Kitajima, N | 1 |
| Fukuda, M | 1 |
| Satomi, Y | 1 |
| Takahashi, T | 1 |
| Yamaguchi, T | 1 |
| Shiozaki, H | 1 |
| Höfner, K | 3 |
| Mori, S | 1 |
| Sakai, Y | 1 |
| Nakajima, K | 1 |
| Ushiroyama, T | 1 |
| Ikeda, A | 1 |
| Ueki, M | 1 |
| Oka, T | 1 |
| Nakano, K | 1 |
| Kirimoto, T | 1 |
| Matsuura, N | 1 |
| Miyazaki, K | 1 |
| Ishida, T | 1 |
| Fujita, Y | 1 |
| Hisazumi, H | 1 |
| Sage, S | 1 |
| Halacka, M | 1 |
| Al-Hasan, A | 1 |
| Voigt, P | 2 |
| Michels, W | 1 |
| Pfestorf, B | 1 |
| Jaeger, HD | 1 |
| Schenk, EM | 1 |
| Kunath, H | 1 |
| Al Hasan, A | 1 |
| Höfner, T | 2 |
| Dieterich, F | 2 |
| Otto-Unger, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder[NCT01640002] | Phase 1 | 42 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population[NCT02385500] | Phase 4 | 5 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to Insufficient or untimely patient recruitment) | ||
| Treatment With Propiverine in Children Suffering From Non-Neurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase III Clinical Trial[NCT00603343] | Phase 3 | 303 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for propiverine and Urinary Incontinence
| Article | Year |
|---|---|
Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.
Topics: Benzhydryl Compounds; Benzilates; Benzofurans; Chronic Disease; Cresols; Drug Combinations; Female; | 2012 |
Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Benzhydryl Compounds; Benzila | 2005 |
The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.
Topics: Administration, Cutaneous; Administration, Intravesical; Administration, Oral; Algorithms; Animals; | 2006 |
19 trials available for propiverine and Urinary Incontinence
| Article | Year |
|---|---|
Efficacy of propiverine hydrochloride for urinary incontinence after robot-assisted or laparoscopic radical prostatectomy.
Topics: Benzilates; Humans; Laparoscopy; Male; Prostatectomy; Prostatic Neoplasms; Quality of Life; Robotics | 2021 |
Therapeutic effect of propiverine hydrochloride on mixed-type urinary incontinence in women: The Female Urgency and Stress Urinary Incontinence Study of Propiverine Hydrochloride trial.
Topics: Aged; Aged, 80 and over; Benzilates; Female; Humans; Japan; Middle Aged; Muscarinic Antagonists; Pro | 2018 |
Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aged, 80 and over; Benzilates; Blood | 2019 |
A randomised, prospective double-blind, propiverine-controlled trial of imidafenacin in patients with overactive bladder.
Topics: Benzilates; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imidazoles; Male; Middle | 2014 |
[The elderly patient with urge incontinence or urge-stress incontinence - efficacy and cardiac safety of propiverine].
Topics: Age Factors; Aged; Benzilates; Calcium Channel Blockers; Cholinergic Antagonists; Data Interpretatio | 2003 |
[Therapy for overactive detrusor using propiverine].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzilates; Causality; Comorbidity; Female; Germany; Hum | 2005 |
Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial.
Topics: Adult; Aged; Benzilates; Female; Humans; Middle Aged; Muscarinic Antagonists; Prospective Studies; R | 2005 |
Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder.
Topics: Adult; Benzhydryl Compounds; Benzilates; Calcium Channel Blockers; Cresols; Double-Blind Method; Fem | 2005 |
Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter st
Topics: Adrenergic alpha-Antagonists; Aged; Benzilates; Comorbidity; Delayed-Action Preparations; Doxazosin; | 2005 |
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome.
Topics: Benzilates; Cross-Over Studies; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions | 2006 |
Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Topics: Benzilates; Child; Cholinergic Antagonists; Double-Blind Method; Female; Humans; Male; Urinary Bladd | 2009 |
Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzilates; Dose-Response Relationship, Drug; Female; | 1995 |
Clinical effect of propiverine in patients with urge or stress incontinence. Kobe University Incontinence Study Group.
Topics: Activities of Daily Living; Benzilates; Female; Humans; Male; Parasympatholytics; Urinary Incontinen | 1998 |
[Clinical effect of propiverine hydrochloride on urinary incontinence].
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Female; Humans; Male; Middle Aged; Parasympatholytics; U | 1998 |
[Long-term administration study of propiverine hydrochloride (BUP-4 tablets) in pollakiuria and urinary incontinence].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzilates; Calcium Channel Blockers; Choliner | 1998 |
A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence.
Topics: Benzilates; Double-Blind Method; Female; Humans; Male; Mandelic Acids; Middle Aged; Parasympatholyti | 1999 |
[Bladder dysfunction in dementia patients showing urinary incontinence: evaluation with cystometry and treatment with propiverine hydrochloride].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Benzilates; Female; Humans; Male; Parasympatholytics; Ur | 1999 |
Clinical efficacy of clenbuterol and propiverine in menopausal women with urinary incontinence: improvement in quality of life.
Topics: Aged; Benzilates; Clenbuterol; Female; Humans; Middle Aged; Parasympatholytics; Postmenopause; Quali | 2000 |
[Comparative studies of the effect of mictonorm (propiverin hydrochloride) and Spasuret (flavoxate hydrochloride) on the bladder detrusor muscle].
Topics: Benzilates; Clinical Trials as Topic; Flavonoids; Flavoxate; Humans; Middle Aged; Parasympatholytics | 1989 |
26 other studies available for propiverine and Urinary Incontinence
| Article | Year |
|---|---|
What Are Realistic Expectations to Become Free of Overactive Bladder Symptoms? Experience from Non-interventional Studies with Propiverine.
Topics: Benzilates; Humans; Motivation; Nocturia; Treatment Outcome; Urinary Bladder, Overactive; Urinary In | 2022 |
Evaluation of Usefulness of Propiverine Hydrochloride in Poor Responders to Previous Anticholinergics.
Topics: Aged; Benzilates; Drug Administration Schedule; Drug Substitution; Female; Humans; Male; Medication | 2018 |
Re: Daniela Marshall-Kehrel, Cornelia Feustel, Charlotta Persson de Geeter, et al. Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical
Topics: Adult; Benzilates; Child; Cholinergic Antagonists; Constipation; Female; Humans; Male; Urinary Bladd | 2009 |
Responsiveness and minimal clinically important change in overactive bladder symptom score.
Topics: Aged; Benzilates; Cholinergic Antagonists; Female; Humans; Male; Middle Aged; Quality of Life; ROC C | 2011 |
Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: results of a prospective long-term study.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Cohort Studies; Cystoscopy | 2012 |
Effects of propiverine hydrochloride, an anticholinergic agent, on urethral continence mechanisms and plasma catecholamine concentration in rats.
Topics: Administration, Intravenous; Animals; Benzilates; Body Weight; Catecholamines; Drug Evaluation, Prec | 2013 |
Application of clenbuterol in the treatment of urinary incontinence.
Topics: Adrenergic beta-Agonists; Adult; Aged; Benzilates; Cholinergic Antagonists; Clenbuterol; Drug Therap | 2001 |
[Urinary incontinence--treatment].
Topics: Adrenergic Uptake Inhibitors; Behavior Therapy; Benzhydryl Compounds; Benzilates; Biofeedback, Psych | 2003 |
An empirical treatment algorithm for incontinent children.
Topics: Adolescent; Algorithms; Benzilates; Child; Child, Preschool; Cholinergic Antagonists; Female; Humans | 2004 |
[Pharmacological evaluation of efficacy and safety of propiverine hydrochloride in patients of overactive bladder--relationship between urodynamic observation and propiverine pharmacokinetics--].
Topics: Aged; Benzilates; Female; Humans; Male; Parasympatholytics; Urinary Bladder, Neurogenic; Urinary Inc | 2005 |
Urodynamic effects of propiverine hydrochloride in children with neurogenic detrusor overactivity: a prospective analysis.
Topics: Adolescent; Benzilates; Child; Child, Preschool; Drug Evaluation; Humans; Infant; Parasympatholytics | 2006 |
[Propiverine hydrochloride improved correlatively subjective QOL and objective findings in Japanese patients with urinary frequency and/or incontinence].
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Drug Administration Schedule; Female; Humans; Male; Midd | 2006 |
Analysis of pharmacological effects of drugs used for treatment of urinary disturbance based on anticholinergic and smooth muscle-relaxing effects.
Topics: Animals; Benzilates; Butylamines; Guinea Pigs; Humans; Mandelic Acids; Muscarinic Antagonists; Muscl | 2007 |
Editorial comment on: Treatment with propiverine in children suffering from nonneurogenic overactive bladder and urinary incontinence: results of a randomized placebo-controlled phase 3 clinical trial.
Topics: Benzilates; Child; Cholinergic Antagonists; Clinical Trials, Phase III as Topic; Humans; Randomized | 2009 |
[Treatment of the symptoms of urinary urge and urge incontinence with propiverin hydrochloride (Mictonorm)].
Topics: Adult; Benzilates; Drug Evaluation; Female; Humans; Middle Aged; Parasympatholytics; Time Factors; U | 1984 |
[Diagnosis, classification and therapy of urge incontinence].
Topics: Benzilates; Biofeedback, Psychology; Electromyography; Female; Humans; Manometry; Parasympatholytics | 1983 |
Effect of NS-21, an anticholinergic drug with calcium antagonistic activity, on lower urinary tract function in a rat model of urinary frequency.
Topics: Animals; Atropine; Benzilates; Calcium Channel Blockers; Denervation; Disease Models, Animal; Flavox | 1997 |
[Tolerance and effectiveness of propiverine hydrochloride in 752 patients with symptoms of detrusor hyperactivity and increased sensitivity and irritability of the urinary bladder: results of a study monitoring drug utilization].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzilates; Child; Child, Preschool; Enuresis; Female; H | 1997 |
Effects of antimuscarinic drugs on both urinary frequency and cognitive impairment in conscious, nonrestrained rats.
Topics: Administration, Oral; Animals; Basal Nucleus of Meynert; Benzilates; Cognition Disorders; Consciousn | 2001 |
[Experience in the use of propiverine hydrochloride (P-4) for patients suffering from urinary frequency and/or incontinence].
Topics: Adult; Aged; Aged, 80 and over; Benzilates; Drug Evaluation; Female; Humans; Male; Middle Aged; Para | 1990 |
[Treatment of symptomatic urinary incontinence in women].
Topics: Benzilates; Female; Humans; Parasympatholytics; Urinary Incontinence | 1989 |
[Cholinolytic treatment of pediatric bladder instability with Mictonetten].
Topics: Adolescent; Benzilates; Child; Child, Preschool; Female; Humans; Male; Parasympatholytics; Urinary B | 1986 |
[Personal experiences with conservative drug therapy of urgency symptoms in the female].
Topics: Benzilates; Clenbuterol; Drug Therapy, Combination; Female; Humans; Middle Aged; Parasympatholytics; | 1986 |
[Effect of Mictonorm (propiverin hydrochloride) on the female urethra].
Topics: Adult; Benzilates; Female; Humans; Parasympatholytics; Urethra; Urinary Incontinence; Urodynamics | 1986 |
[Treatment of the unstable bladder in children with the anticholinergic agent propiverin hydrochloride (mictonorm/mictonets)].
Topics: Benzilates; Child; Dose-Response Relationship, Drug; Enuresis; Humans; Parasympatholytics; Urinary I | 1985 |
[Changes induced by Mictonorm in the urodynamics of the detrusor muscle in females with symptoms of the urge to urinate].
Topics: Adult; Benzilates; Compliance; Female; Humans; Muscle, Smooth; Parasympatholytics; Urinary Bladder; | 1985 |